CN106536544B - 艰难梭菌免疫原性组合物 - Google Patents

艰难梭菌免疫原性组合物 Download PDF

Info

Publication number
CN106536544B
CN106536544B CN201580039744.7A CN201580039744A CN106536544B CN 106536544 B CN106536544 B CN 106536544B CN 201580039744 A CN201580039744 A CN 201580039744A CN 106536544 B CN106536544 B CN 106536544B
Authority
CN
China
Prior art keywords
seq
cdtb
protein
cdta
clostridium difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580039744.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106536544A (zh
Inventor
C.卡施塔多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN106536544A publication Critical patent/CN106536544A/zh
Application granted granted Critical
Publication of CN106536544B publication Critical patent/CN106536544B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580039744.7A 2014-06-25 2015-06-25 艰难梭菌免疫原性组合物 Active CN106536544B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1411306.2 2014-06-25
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition
GB1411371.6 2014-06-26
PCT/EP2015/064324 WO2015197737A1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition

Publications (2)

Publication Number Publication Date
CN106536544A CN106536544A (zh) 2017-03-22
CN106536544B true CN106536544B (zh) 2020-04-07

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039744.7A Active CN106536544B (zh) 2014-06-25 2015-06-25 艰难梭菌免疫原性组合物

Country Status (17)

Country Link
US (1) US20170218031A1 (enExample)
EP (2) EP3160500B1 (enExample)
JP (2) JP6688233B2 (enExample)
CN (1) CN106536544B (enExample)
BE (1) BE1022949B1 (enExample)
BR (1) BR112016030096B1 (enExample)
CY (1) CY1122145T1 (enExample)
DK (1) DK3160500T3 (enExample)
ES (1) ES2749701T3 (enExample)
HR (1) HRP20191864T1 (enExample)
HU (1) HUE045936T2 (enExample)
LT (1) LT3160500T (enExample)
MX (1) MX374380B (enExample)
PL (1) PL3160500T3 (enExample)
PT (1) PT3160500T (enExample)
SI (1) SI3160500T1 (enExample)
WO (1) WO2015197737A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691609B (zh) * 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
EP1169456B1 (en) * 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2012349753A1 (en) * 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clostridium botulinum C2 toxin: Identification of the binding site for chloroquine and related compounds and influence of the binding site on properties of the C2II channel;T.neumeyer等;《Journal of biological chemistry》;20071211;第283卷(第7期);全文 *
Expression,purification and cell cytotoxicity of actin-modifying binary toxin from clostridium difficile;Sunriyal A等;《Protein expression and purification》;20101101;第74卷(第1期);全文 *

Also Published As

Publication number Publication date
PL3160500T3 (pl) 2020-02-28
CN106536544A (zh) 2017-03-22
BR112016030096A8 (pt) 2021-07-06
PT3160500T (pt) 2019-11-11
HRP20191864T1 (hr) 2020-01-10
EP3636278A2 (en) 2020-04-15
CA2952118A1 (en) 2015-12-30
EP3160500A1 (en) 2017-05-03
EP3160500B1 (en) 2019-08-21
DK3160500T3 (da) 2019-11-11
JP2017520573A (ja) 2017-07-27
BE1022949A1 (fr) 2016-10-21
US20170218031A1 (en) 2017-08-03
SI3160500T1 (sl) 2019-11-29
CY1122145T1 (el) 2020-11-25
LT3160500T (lt) 2019-10-25
MX374380B (es) 2025-03-06
EP3636278A3 (en) 2020-07-15
MX2016017094A (es) 2017-05-03
WO2015197737A1 (en) 2015-12-30
HUE045936T2 (hu) 2020-01-28
BE1022949B1 (fr) 2016-10-21
BR112016030096A2 (pt) 2017-08-22
JP6688233B2 (ja) 2020-04-28
JP2020100625A (ja) 2020-07-02
BR112016030096B1 (pt) 2023-10-03
ES2749701T3 (es) 2020-03-23

Similar Documents

Publication Publication Date Title
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
DK2248822T3 (en) MENINGOCOKKER ADHESIONS
JP5139618B2 (ja) Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
KR102393038B1 (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
JP2004520803A (ja) 尋常性挫瘡の治療および診断のための組成物および方法
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
US20180305416A1 (en) Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
JP2020100625A (ja) クロストリジウム・ディフィシル免疫原性組成物
JP2015528457A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CA2952118C (en) Clostridium difficile immunogenic composition
BE1022553A1 (fr) Mutants de spy0269
JP2015532594A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
BE1022553B1 (fr) Mutants de spy0269
WO2020039033A1 (en) Immunogenic proteins and compositions
JP2018134074A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant